行情

IONS

IONS

Isis Pharms
NASDAQ

实时行情|Nasdaq Last Sale

60.38
+0.69
+1.16%
盘后: 60.30 -0.08 -0.13% 19:57 11/21 EST
开盘
59.68
昨收
59.69
最高
60.72
最低
59.36
成交量
95.13万
成交额
--
52周最高
86.58
52周最低
48.27
市值
84.93亿
市盈率(TTM)
88.00
分时
5日
1月
3月
1年
5年

分析师评级

18位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IONS 新闻

  • WTO:G20贸易壁垒已处“历史最高水平”
  • 新浪财经.3小时前
  • 收盘:美股连续三天下跌 芯片股跌幅明显
  • 新浪美股.3小时前
  • 众议院民主党与特朗普政府未能就USMCA达成协议
  • 新浪财经.3小时前
  • 梅西百货同店销售两年来首现下滑 Q3净利润大降97%
  • 新浪财经.6小时前

更多

所属板块

生物技术和医学研究
-0.31%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

IONS 简况

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
展开

Webull提供Ionis Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。